Intravesical mitomycin C for the treatment of recurrent superficial bladder tumours

Br J Urol. 1987 Mar;59(3):239-41. doi: 10.1111/j.1464-410x.1987.tb04614.x.

Abstract

Forty-three patients with recurrent multiple superficial bladder tumours (Tis, Ta and Tl) were treated with Mitomycin C 20 mg in 20 ml water intravesically weekly for 8 to 12 weeks, and monthly instillations were continued for 5 to 6 months. Residual tumour was resected at 12 weeks, at which time 40 patients (93%) showed a response to treatment. A complete response was seen in 24 (56%) and 16 (37%) showed a partial response. After a follow-up of 12 to 48 months (median 19), 19 of 33 evaluable patients (58%) have shown tumour recurrence. Invasive tumour has developed in seven (17%) and transitional cell tumours of the ureter in two of those patients who showed an initial response to treatment.

MeSH terms

  • Administration, Intravesical
  • Humans
  • Mitomycin
  • Mitomycins / administration & dosage*
  • Mitomycins / adverse effects
  • Mitomycins / therapeutic use
  • Neoplasm Recurrence, Local
  • Neoplasm Staging
  • Urinary Bladder Neoplasms / drug therapy*
  • Urinary Bladder Neoplasms / pathology

Substances

  • Mitomycins
  • Mitomycin